M Elvira Balcells1, Nicole Le Corre2,3, Josefina Durán4, María Elena Ceballos1, Cecilia Vizcaya2, Sebastián Mondaca5, Martín Dib6, Ricardo Rabagliati1, Mauricio Sarmiento5, Paula I Burgos4, Manuel Espinoza7, Marcela Ferrés2,3, Constanza Martinez-Valdebenito2,3, Cinthya Ruiz-Tagle1, Catalina Ortiz6, Patricio Ross8, Sigall Budnik4, Sandra Solari9, María de Los Ángeles Vizcaya8, Hanns Lembach10, Roslye Berrios-Rojas11,12, Felipe Melo-González11,12, Mariana Ríos11,12, Alexis M Kalergis11,12,13, Susan M Bueno11,12, Bruno Nervi5. 1. Departamento de Enfermedades Infecciosas del Adulto, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Departamento de Enfermedades Infecciosas e Inmunologia Pediatrica. Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile. 3. Laboratorio de Infectología y Virología Molecular, Red de Salud UC-CHRISTUS, Santiago, Chile. 4. Departamento de Reumatología e Inmunología Clínica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 5. Departamento de Hematología y Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 6. Programa de Trasplante, Departamento de Cirugía Digestiva, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 7. Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 8. Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 9. Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 10. Instituto Clinico de Transplantes, Hospital Clínico Universidad de Chile and Facultad de Medicina, Universidad de Chile, Santiago, Chile. 11. Millennium Institute on Immunology and Immunotherapy, Santiago, Chile. 12. Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chileand. 13. Departamento de Endocrinología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract
BACKGROUND: Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been widely implemented in low- and middle-income countries. However, immunogenicity in immunocompromised patients has not been established. Herein, we aimed to evaluate immune response to CoronaVac vaccine in these patients. METHODS: This prospective cohort study included 193 participants with 5 different immunocompromising conditions and 67 controls, receiving 2 doses of CoronaVac 8-12 weeks before enrollment. The study was conducted between May and August 2021, at Red de Salud UC-CHRISTUS, Santiago, Chile. Neutralizing antibody (NAb) positivity, total anti-SARS-CoV-2 immunoglobulin G antibody (TAb) concentrations, and T-cell responses were determined. RESULTS: NAb positivity and median neutralizing activity were 83.1% and 51.2% for the control group versus 20.6% and 5.7% (both P < .001) in the solid organ transplant group, 41.5% and 19.2% (both P < .0001) in the autoimmune rheumatic diseases group, 43.3% (P < .001) and 21.4% (P<.01 or P = .001) in the cancer with solid tumors group, 45.5% and 28.7% (both P < .001) in the human immunodeficiency virus (HIV) infection group, 64.3% and 56.6% (both differences not significant) in the hematopoietic stem cell transplant group, respectively. TAb seropositivity was also lower for the solid organ transplant (20.6%; P < .0001), rheumatic diseases (61%; P < .001), and HIV groups (70.9%; P = .003), compared with the control group (92.3%). On the other hand, the number of interferon γ spot-forming T cells specific for SARS-CoV-2 tended to be lower in all immunocompromising conditions but did not differ significantly between groups. CONCLUSIONS: Diverse immunocompromising conditions markedly reduce the humoral response to CoronaVac vaccine. These findings suggest that a boosting vaccination strategy should be considered in these vulnerable patients. CLINICAL TRIALS REGISTRATION: NCT04888793.
BACKGROUND: Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been widely implemented in low- and middle-income countries. However, immunogenicity in immunocompromised patients has not been established. Herein, we aimed to evaluate immune response to CoronaVac vaccine in these patients. METHODS: This prospective cohort study included 193 participants with 5 different immunocompromising conditions and 67 controls, receiving 2 doses of CoronaVac 8-12 weeks before enrollment. The study was conducted between May and August 2021, at Red de Salud UC-CHRISTUS, Santiago, Chile. Neutralizing antibody (NAb) positivity, total anti-SARS-CoV-2 immunoglobulin G antibody (TAb) concentrations, and T-cell responses were determined. RESULTS: NAb positivity and median neutralizing activity were 83.1% and 51.2% for the control group versus 20.6% and 5.7% (both P < .001) in the solid organ transplant group, 41.5% and 19.2% (both P < .0001) in the autoimmune rheumatic diseases group, 43.3% (P < .001) and 21.4% (P<.01 or P = .001) in the cancer with solid tumors group, 45.5% and 28.7% (both P < .001) in the human immunodeficiency virus (HIV) infection group, 64.3% and 56.6% (both differences not significant) in the hematopoietic stem cell transplant group, respectively. TAb seropositivity was also lower for the solid organ transplant (20.6%; P < .0001), rheumatic diseases (61%; P < .001), and HIV groups (70.9%; P = .003), compared with the control group (92.3%). On the other hand, the number of interferon γ spot-forming T cells specific for SARS-CoV-2 tended to be lower in all immunocompromising conditions but did not differ significantly between groups. CONCLUSIONS: Diverse immunocompromising conditions markedly reduce the humoral response to CoronaVac vaccine. These findings suggest that a boosting vaccination strategy should be considered in these vulnerable patients. CLINICAL TRIALS REGISTRATION: NCT04888793.
Authors: Hope R Lapointe; Francis Mwimanzi; Peter K Cheung; Yurou Sang; Fatima Yaseen; Gisele Umviligihozo; Rebecca Kalikawe; Sarah Speckmaier; Nadia Moran-Garcia; Sneha Datwani; Maggie C Duncan; Olga Agafitei; Siobhan Ennis; Landon Young; Hesham Ali; Bruce Ganase; F Harrison Omondi; Winnie Dong; Junine Toy; Paul Sereda; Laura Burns; Cecilia T Costiniuk; Curtis Cooper; Aslam H Anis; Victor Leung; Daniel Holmes; Mari L DeMarco; Janet Simons; Malcolm Hedgcock; Natalie Prystajecky; Christopher F Lowe; Ralph Pantophlet; Marc G Romney; Rolando Barrios; Silvia Guillemi; Chanson J Brumme; Julio S G Montaner; Mark Hull; Marianne Harris; Masahiro Niikura; Mark A Brockman; Zabrina L Brumme Journal: medRxiv Date: 2022-03-23
Authors: Daniel Leung; Xiaofeng Mu; Jaime S Rosa Duque; Samuel M S Cheng; Manni Wang; Wenyue Zhang; Yanmei Zhang; Issan Y S Tam; Toby S S Lee; Jennifer H Y Lam; Sau Man Chan; Cheuk Hei Cheang; Yuet Chung; Howard H W Wong; Amos M T Lee; Wing Yan Li; Sara Chaothai; Leo C H Tsang; Gilbert T Chua; Kai-Ning Cheong; Elaine Y L Au; Janette S Y Kwok; Koon Wing Chan; Patrick C Y Chong; Pamela P W Lee; Marco H K Ho; Tsz Leung Lee; Wenwei Tu; Malik Peiris; Yu Lung Lau Journal: Front Immunol Date: 2022-09-20 Impact factor: 8.786
Authors: Martín Dib; Nicole Le Corre; Catalina Ortiz; Daniel García; Marcela Ferrés; Constanza Martinez-Valdebenito; Cinthya Ruiz-Tagle; María José Ojeda; Manuel A Espinoza; Aquiles Jara; Juan Pablo Arab; Ricardo Rabagliati; Cecilia Vizcaya; María Elena Ceballos; Mauricio Sarmiento; Sebastián Mondaca; Macarena Viñuela; Antonia Pastore; Vania Szwarcfiter; Elizabeth Galdames; Aldo Barrera; Pablo Castro; Nicolás Ms Gálvez; Jorge A Soto; Susan M Bueno; Alexis M Kalergis; Bruno Nervi; M Elvira Balcells Journal: Lancet Reg Health Am Date: 2022-09-23